Grindeks

JSC Grindeks (branded as Grindex), is a Latvian company listed on the Nasdaq Riga with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.[1]

AS Grindeks
TypePublic
Nasdaq Baltic: GRD1R
IndustryPharmaceuticals
Founded11 October 1991[1]
Headquarters
Riga
,
Latvia
Area served
Worldwide
Key people
Kirovs Lipmans (Chairman)[2]
Juris Hmelnickis (CEO)
Janis Romanovskis (Chief Finance and Administrative Officer)
Revenue141,400,000 euro (2019) 
Number of employees
1355 (2017)[3]
SubsidiariesJSC Kalceks , Tallinn Pharmaceutical Plant , HBM Pharma
Websitewww.grindeks.eu

Based in Riga, the Baltics, Grindeks is a vertically integrated pharmaceutical company with the history from 1946. Its main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients.

The company specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate.[4][5][6] Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.[7][8][9][10][11]

In 2018, Grindeks turnover reached €145.5 million.[12] Grindeks had 1355 employees.[3]

Patron of the University of Latvia. Grindeks is a bronze patron of the University of Latvia Foundation. In 2004, "Grindeks" donated funds for the modernization of the equipment of the Medical Faculty of the University of Latvia.[13]

Main building of the company

References
  1. "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. 27 April 2010. p. 3. Archived from the original (PDF) on 21 December 2016. Retrieved 1 November 2010.
  2. "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. p. 5. Archived from the original (PDF) on 21 December 2016. Retrieved 1 November 2016.
  3. "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. p. 34. Archived from the original (PDF) on 21 December 2016. Retrieved 1 November 2010.
  4. Biotech Intelligence. http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html Archived 19 July 2012 at Archive.today (accessed 17 May 2012).
  5. PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data. "Archived copy". Archived from the original on 28 July 2012. Retrieved 13 June 2012.CS1 maint: archived copy as title (link) (accessed 17 May 2012).
  6. Evaluate Pharma. "Archived copy". Archived from the original on 17 December 2012. Retrieved 13 June 2012.CS1 maint: archived copy as title (link) (accessed 17 May 2012).
  7. Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA (March 2006). "Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics". J. Cardiovasc. Pharmacol. 47 (3): 493–9. doi:10.1097/01.fjc.0000211732.76668.d2. PMID 16633095.
  8. Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M (December 2006). "Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction". J. Cardiovasc. Pharmacol. 48 (6): 314–9. doi:10.1097/01.fjc.0000250077.07702.23. PMID 17204911.
  9. Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N (May 2000). "Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction". Eur. J. Pharmacol. 395 (3): 217–24. doi:10.1016/S0014-2999(00)00098-4. PMID 10812052.
  10. Leung IK, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TD, Oppermann U, McDonough MA, Schofield CJ (December 2010). "Structural and mechanistic studies on γ-butyrobetaine hydroxylase". Chem. Biol. 17 (12): 1316–24. doi:10.1016/j.chembiol.2010.09.016. PMID 21168767.
  11. Tars K, Rumnieks J, Zeltins A, Kazaks A, Kotelovica S, Leonciks A, Sharipo J, Viksna A, Kuka J, Liepinsh E, Dambrova M (August 2010). "Crystal structure of human gamma-butyrobetaine hydroxylase". Biochem. Biophys. Res. Commun. 398 (4): 634–9. doi:10.1016/j.bbrc.2010.06.121. PMID 20599753.
  12. "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. p. 7. Archived from the original (PDF) on 21 December 2016. Retrieved 1 November 2016.
  13. https://www.fonds.lv/lepojamies/mecenati/bronzas-mecenati/as-grindeks/


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.